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Can lymphangiosarcoma be resurrected? A clinicopathological and immunohistochemical
study of lymphatic differentiation in 49 angiosarcomas
Aims: The term lymphangiosarcoma has largely been
abandoned in the current classification of endothelial
neoplasms. Recently, a number of lymphatic-associated
antibodies have been developed for immunohistochem-
istry, which frequently stain angiosarcomas, implying
lymphatic or mixed lymphatic and blood vascular
differentiation is common. The aim was to investigate
further lymphatic antigen expression, and to explore
the relation of immunohistochemistry to morphological
and clinical findings.
Methods and results: Forty-nine angiosarcomas in
tissue microarrays were analysed with D2-40 and
antibodies to Prox-1 and vascular endothelial growth
factor receptor (VEGFR)-3. D2-40 was positive in 53%,
Prox-1 in 76%, and VEGFR-3 in 57%. Tumours with
features attributable to lymphatic differentiation such
as hobnail and kaposiform morphologies were more
often positive with these markers, including a statistical
association between D2-40 and hobnailing. Ten
tumours had features suggestive of lymphatic differen-
tiation, namely well-differentiated histology, interanas-
tomosing channels devoid of red cells, prominent
hobnailing, lymphoid aggregates, and multi-antigen
expression of D2-40 (100%), Prox-1 (100%) and
VEGFR-3 (60%), which might be deserving of the
appellation lymphangiosarcoma. Nine were cutaneous
scalp ⁄ facial tumours in elderly patients and one arose
within chronic lymphoedema.
Conclusions: Lymphatic differentiation is common in
angiosarcoma, certain subsets show greater lymphatic
differentiation than others, and lymphangiosarcoma
may be defined pathologically, rather than clinically.
Keywords: angiosarcoma, D2-40, immunohistochemistry, lymphangiosarcoma, podoplanin, Prox-1, VEGFR-3
Abbreviations: LYVE-1, lymphatic vessel hyaluronan receptor-1; TMA, tissue microarray; VEGFR, vascular
endothelial growth factor receptor
Introduction
The concept of lymphangiosarcoma originated in 1948
when Stewart and Treves described six cases of a
malignant vascular neoplasm that arose in the upper
extremity many years after radical mastectomy.1
Because the neoplasm arose in the setting of chronic
lymphoedema, it was presumed to have arisen from
lymphatic vessels, thus having lymphatic endothelial
differentiation. Today pathologists rarely make this
diagnosis, and distinguishing between lymphangiosar-
coma and haemangiosarcoma has essentially become
an obsolete practice. This is summarized in Enzinger
and Weiss’s Soft tissue tumors textbook: ‘Since it is
usually impossible to determine which tumors display
lymphatic versus vascular differentiation, all are
referred to as angiosarcoma, even those that arise in
the setting of lymphedema’.2
Recently, a number of antigens preferentially
expressed by lymphatic endothelial cells have been
discovered. Examples include podoplanin (recognized
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by the monoclonal antibody D2-40), Prox-1, vascular
endothelial growth factor receptor (VEGFR)-3, and
lymphatic vessel hyaluronan receptor-1 (LYVE-1), all
of which have been used to study vascular tumours by
immunohistochemistry. These antigens are expressed in
nearly all lymphangiomas,3–9 but in only a minority of
haemangiomas.4,5,7–12 They are also expressed in nearly
all Kaposi sarcomas,3–5,7,8,11,13 a tumour believed to
have at least partial lymphatic differentiation. Data
about expression of lymphatic antigens in angiosarco-
ma, however, are limited.3–5,8,11,14 For example, only
one group has studied a large number of cases,4 only
single antigens have been studied in all but one series,15
and Prox-1 has not been studied at all. Some studies
suggest that most angiosarcomas show some degree of
lymphatic differentiation,3,4,8,14 whereas others suggest
that certain subsets show lymphatic differentiation and
suggest a link between expression of lymphatic antigens
and morphological features such as hobnail cytol-
ogy,5,11 non-epithelioid cytology,4,15 kaposiform archi-
tecture,11 and lymphoid infiltrates or aggregates.5,11
The purpose of our study was to analyse a large number
of angiosarcomas by immunohistochemistry with
D2-40, and antibodies to Prox-1 and VEGFR-3 to
determine the extent of lymphatic antigen expression.
In addition, we wanted to see if we could identify a
subgroup of angiosarcomas that might be considered
lymphangiosarcomas based upon morphological,
immunohistochemical and clinical features.
Materials and methods
This study was conducted under approval of the
Institutional Review Board of the University of Mich-
igan. The pathology database was searched for all
angiosarcomas diagnosed between 1986 and 2006.
Forty-nine cases had sufficient tissue in paraffin blocks
for immunohistochemical studies. Each case was
classified as sporadic cutaneous, sporadic visceral ⁄
deep-seated, lymphoedema-associated or radiation-
associated based upon information gleaned from the
medical records. Haematoxylin and eosin-stained
sections were re-examined to confirm the diagnosis.
The following features were evaluated: differentiation
(well, moderate or poor, based upon criteria of the
French Federation of Cancer Centre Systems), archi-
tecture (vasoformative, fascicular ⁄ kaposiform or solid),
cytology (hobnail, epithelioid, spindled or pleomorphic)
and presence or absence of lymphoid aggregates within
the tumour. Cuboidal cells with scant cytoplasm and
apical hyperchromatic nuclei that protruded into the
vascular lumen were considered hobnail cells, whereas
cells with abundant eosinophilic cytoplasm and vesic-
ular nuclei with prominent nucleoli were considered
epithelioid cells. The series did not include any low-
grade malignant vascular tumour such as retiform
haemangioendothelioma or Dabska tumour, tumours
with frequent hobnailing.
Tissue microarrays (TMAs) with three 1.0-mm
punches of each tumour were constructed and
immunostained with D2-40 and antibodies to Prox-1
and VEGFR-3. Table 1 details the antibodies and
conditions. A variety of normal tissue samples and
neoplasms were included in the TMAs as controls.
TMAs were utilized to facilitate screening of multiple
tumours with multiple antibodies. In tumours show-
ing cytoarchitectural heterogeneity, tissue cores were
selectively taken to sample for variation. In addition,
whole block tissue sections were stained in 23
tumours. These included nine tumours that were
underrepresented in the TMA, such as ones in which
the core sections were lost in processing. Cytoplasmic
immunoreactivity was considered positive for D2-40
and VEGFR-3, whereas nuclear reactivity was consid-
ered positive for Prox-1. For 14 tumours with mixed
well and poorly differentiated areas, selected whole
blocks were stained to analyse for variation in
patterns of reactivity based upon histological grade.
A separate TMA block containing five lymphangio-
mas, four haemangiomas and six Kaposi sarcomas
was used for antibody validation.
Correlative analyses between tumours having hob-
nail cytology and ⁄ or kaposiform architecture (mor-
phological features often attributed to tumours with
lymphatic differentiation) and immunopositivity with
D2-40, Prox-1 and ⁄ or VEGFR-3 were performed using
Table 1. Antibodies and procedures
Antibody Species Manufacturer Address Dilution Pretreatment
D2-40 Mouse Signet Dedham, MA, USA 1:50 None
Prox-1 Rabbit Abcam Cambridge, MA, USA 1:100 HIER pH 6
VEGFR-3 Rabbit Abcam Cambridge 1:150 HIER pH 6
HIER, heat-induced epitope retrieval.
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histograms and Fisher’s exact test. A P-value of <0.05
was considered statistically significant.
Results
Among the 49 angiosarcomas, 22 were sporadic
cutaneous tumours (18 of the scalp or face, and one
each on the back, ante cubit, vulva and buttock), 15
were sporadic visceral ⁄ deep-seated tumours (five
breast, three heart, and one each involving mediasti-
num, thigh, adrenal gland, retroperitoneum, aorta,
maxillary sinus, and femur), eight were radiation-
associated (five breast, one scrotum, one suprapubic
skin, and one oral mucosa) and four were lymph-
oedema-associated (all involving the lower extremity).
Nineteen tumours had well-differentiated areas, 42 had
moderately or poorly differentiated areas. Fourteen
tumours had both well and poorly differentiated areas
within the same tumour. Architectural features were
vasoformative in 38, solid in 28, and kaposiform ⁄ fas-
cicular in 11. Cytological features were epithelioid in
22, hobnail in 19, spindled in 16, and pleomorphic in
five. Many tumours showed morphological hetero-
geneity in terms of architectural and cytological
features and were therefore included in more than
one group in each category.
Twenty-six tumours (53%) were positive for D2-40,
37 (76%) for Prox-1 and 28 (57%) for VEGFR-3. Of the
14 tumours with mixed well and poorly differentiated
areas in which whole block sections were immunore-
active, there was no variation in reactivity based upon
grade. Of the validation samples, five of five lymph-
angiomas were positive for D2-40 and Prox-1, while
four were positive for VEGFR-3. All four haemangiomas
were negative for D2-40 and VEGFR-3, while one was
positive for Prox-1. Among the six Kaposi sarcomas,
five were positive with D2-40, five for Prox-1 and five
for VEGFR-3 (Table 2).
Tumours with hobnail cytology were more likely to
express lymphatic antigens than those without hobna-
iling (Figure 1). Seventy-nine percent with hobnailing
were positive for D2-40 compared with 37% without
hobnailing, and the difference was statistically signif-
icant (P = 0.01). Eighty-nine percent of tumours with
hobnailing were positive for Prox-1 compared with
67% without, and 68% were positive for VEGFR-3
compared with 50% without. These trends were not
statistically significant (P = 0.09 and P = 0.25 for
Prox-1 and VEGFR-3, respectively). Comparing tu-
mours with and without kaposiform areas, kaposiform
tumours were more often positive for Prox-1 (91%
compared with 71%) and VEGFR-3 (73% compared
with 53%), but less often positive for D2-40 (45%
compared with 55%). None of these differences was
statistically significant.
Among angiosarcomas with hobnail cytology, we
identified a morphologically distinctive subgroup of 10
well-differentiated cutaneous tumours composed of
irregular interanastomosing channels, mostly devoid
of red blood cells, lined by endothelial cells with
prominent hobnailing (Figures 2 and 3). These
tumours also had prominent lymphocytic aggregates
(Figure 4), some with germinal centres. Within this
subgroup were six men and four women, median age
76 years (range 49–82 years). Nine were sporadic
cutaneous tumours of the scalp and face and one was
a lymphoedema-associated tumour of the lower
extremity.
All 10 tumours in this subgroup were positive for
D2-40 and Prox-1, and six were positive for VEGFR-3
(Figure 5). These tumours were significantly more
likely to be positive for D2-40 (P = 0.01) and were
more likely, but not statistically significantly so, to be
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Figure 1. Histogram comparing tumours with and without hobnail
endothelial cells. D2-40 is significantly more often positive, whereas
Prox-1 and VEGFR-3 show a trend towards staining tumours with
hobnailing.
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positive for Prox-1 (P = 0.09) than the other tumours
in our series (Figure 6). By evaluating multi-antigen
expression, six tumours in this subgroup (60%)
expressed all three antigens, compared with only 39%
of the other tumours in our series (P = 0.29). Further-
more, all 10 tumours in this subgroup were positive for
D2-40 and Prox-1, whereas only 41% of other tumours
were positive for both, a statistically significant differ-
ence (P = 0.03). All 10 of these tumours had promi-
nent lymphoid aggregates compared with only 51% of
the remaining tumours, a significant difference
(P = 004). Two of the 10 tumours were purely well-
differentiated angiosarcomas, whereas eight had addi-
tional poorly differentiated areas (Figure 7). In three
tumours the poorly differentiated areas were epithelioid
(Figure 8), in two they were kaposiform ⁄ fascicular, in
one there were both epithelioid and kaposiform ⁄
fascicular areas, and in one the high-grade area was
non-epithelioid. As in all tumours with mixed-grade
histology in our series, the poorly differentiated areas
showed the same antigen profile as the well-differen-
tiated areas in these 10 tumours.
At last follow-up (mean 7 years, range 8 months to
9 years), 60% of these 10 patients had died of disease,
20% were alive with disease, one had died of a cause not
known to us, and one was alive with no evidence of
disease after 9 years. By comparison, among the 39
cases not included in this subgroup 57% had died of
disease, 5% were alive with disease, 19% were alive with
no evidence of disease, 8% were alive but their disease
status was not known to us, and 11% were lost to follow-
up. Clinicopathological and immunohistochemical
features comparing the 10 cases with lymphangiosar-
comatous differentiation with the remaining cases are
summarized in Table 3.
Figure 2. Ten tumours have histological features suggestive of
lymphatic differentiation. All have well-differentiated areas composed




Figure 3. All 10 tumors have prominent hobnail endothelial cells
characterized by cuboidal cells with scant cytoplasm and apical nuclei
protruding into the lumen. (A, Low power; B, high power.)
Figure 4. Lymphocytic infiltrates are prominent in all 10 ‘lymph-
angiosarcomas,’ including frequent lymphoid aggregates.
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Of the four tumours in this study that arose within
a setting of chronic lymphoedema, only one had
prominent hobnailing and was included in the
subgroup of 10 cases just discussed. It was positive
for all three markers. The other three oedema-associ-
ated tumours were high-grade vasoformative and solid
tumours. One was negative for all three markers, one
expressed D2-40 only, and one expressed Prox-1 and
VEGFR-3.
Discussion
Substantial progress has been made in our under-
standing of how the lymphatic vasculature is formed




Figure 5. D2-40 (A) and Prox-1 (B) are positive in all 10


















Figure 6. Histogram comparing the subgroup of tumours with
prominent lymphatic differentiation by histology with the other
tumours. D2-40 was significantly more often positive in the sub-
group, whereas Prox-1 showed a trend toward more frequent
immunoreactivity, and VEGFR-3 showed no trend.
Figure 7. Eight of the 10 ‘lymphangiosarcomas’ have poorly differ-
entiated areas in addition to well-differentiated areas exemplified by
this tumour. Note the low-grade vasoformative area juxtaposed to the
high-grade solid area beneath it.
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mechanisms involved in lymphangiogenesis. The cur-
rent model of lymphatic development theorizes that
lymphatic endothelial cells originate from specific
locations in the embryonic (or cardinal) vein, which
migrate to form lymphatic sacs, and then undergo
further sprouting and remodelling to form the lympha-
tic system.16 All endothelial cells in the embryonic vein
express VEGFR-3. The earliest known event in lymph-
angiogenesis is polarized expression of the homeobox
transcription factor Prox-1, which commits the cell to
lymphatic differentiation.17 As lymphatics develop,
their endothelial cells continue to express VEGFR-3
and Prox-1, then add LYVE-1 (a homologue of CD44),
and finally podoplanin, a small transmembrane mucin-
like protein16 detected with the antibody D2-40. By
contrast, as blood vessels mature, they lose VEGFR-3
expression. Thus, in normal adult tissues lymphatics
express VEGFR-3, Prox-1, LYVE-1 and podoplanin,
whereas blood vessels usually express none of these
antigens.
The specificity of lymphatic endothelial markers for
neoplasms with lymphatic differentiation has been
evaluated in a number of immunohistochemical stud-
ies. For example, D2-40 has been shown to be highly
specific for distinguishing lymphangioma from hae-
mangioma.3,5,6,9,12 VEGFR-3 has also been found to be
highly expressed in lymphangiomas, but is less specific
than D2-40 since it also stained substantial numbers of
haemangiomas, 22 of 45 and 2 of 13, in two separate
studies.4,11 Comparative studies of lymphangioma and
haemangioma using LYVE-1 and Prox-1 are limited to
only one study of each. LYVE-1 stained nine of nine
lymphangiomas and 0 of 20 haemangiomas,8 while
Prox-1 stained five of six lymphangiomas and 5 of 12
haemangiomas.7 In our current analysis of D2-40,
VEGFR-3 and Prox-1, we observed high specificity for
lymphangioma over haemangioma with all three
markers (Table 2).
Although the histogenesis of Kaposi’s sarcoma is not
entirely clear, most investigators regard it as having at
Figure 8. Most often the high-grade areas are epithelioid angio-
sarcomas.
Table 3. Clinicopathological and immunohistochemical com-










Sporadic cutaneous 90% 33%
Scalp ⁄ face (90%) (23%)
Sporadic visceral ⁄ deep 38%
Breast (13%)
Visceral organ (10%)





Hobnail cytology 100% 23%













NED, no evidence of disease; AWD, alive with disease; DOD,
died of disease.
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least partial lymphatic differentiation. Immunohisto-
chemical studies of D2-40, VEGFR-3, Prox-1 and LYVE-1
have demonstrated near 100% sensitivity rates in
Kaposi’s sarcoma.3–5,8,11,13 Similarly, we found high
rates of immunoreactivity in Kaposi’s sarcoma, with five
of six tumours staining with at least one of the three
markers we evaluated (Table 2). Thus, based upon our
results and those from other studies, D2-40, Prox-1 and
VEGFR-3 appear to be rather specific markers of
lymphatic neoplasms.
A number of immunohistochemical studies of
lymphatic differentiation in angiosarcoma have been
published,3–5,8,11,14,15,18,19 most of which have
employed only a single lymphatic endothelial-specific
antibody. Although most of these studies conclude that
angiosarcomas frequently show mixed lymphatic and
blood vascular endothelial differentiation, some suggest
that there may be subsets with at least partial
lymphatic differentiation,11,15 including some that
might be considered lymphangiosarcomas.5
In the largest series of such studies, Partanen et al.4
examined 60 angiosarcomas for VEGFR-3, expression
and found 48 (80%) to be positive. They observed that
epithelioid tumours were less often positive, but con-
cluded that VEGFR-3 lacks specificity for lymphatic
differentiation. By contrast, Folpe et al.11 also staining
for VEGFR-3 found 8 of 16 angiosarcomas to be positive,
and correlated immunopositivity with hobnail histology
and lymphocytic infiltration. They concluded that
angiosarcomas expressing this receptor protein may
represent tumours displaying lymphatic differentiation.
Similarly, in a recent study Itakura et al.15 examined 34
angiosarcomas for multiple VEGFs and VEGFRs. They
found 27 (79%) to stain for VEGFR-3 and, based upon all
their results, concluded that angiosarcoma of the scalp
may include examples of lymphatic origin.
There are three studies of anti-podoplanin or D2-40
in angiosarcoma. In the earliest study, Breiteneder-
Geleff et al.14 found 10 of 11 angiosarcomas to be
positive for podoplanin, and concluded that most
angiosarcomas show a mixed phenotype. By contrast,
Kahn et al.5 found three of seven angiosarcomas to
stain with D2-40. They observed that immunopositiv-
ity correlated with hobnail histology and lymphoid
aggregates, and concluded that a subset of angiosar-
comas can undergo at least partial differentiation along
the lymphatic endothelial lineage and could be classi-
fied as lymphangiosarcomas. More recently, Fukunaga
et al.3 found 7 of 15 angiosarcomas to be D2-40+,
which correlated with epithelioid and papillary endo-
thelial cells, and concluded that there may be a subset
of angiosarcoma with dual vascular and lymphatic
endothelial phenotypes.
Only one study of LYVE-1 expression in angiosarco-
ma has been published,8 in which all 10 tumours were
positive. The authors concluded that angiosarcomas
show characteristics of both lymphatic and blood vessel
phenotypes. An older study from 1987 by Holden
et al.19 using periodate-lysine paraformaldehyde fixa-
tive and the antibodies to EN4, PAL-E and factor VIII-
related antigen and electron microscopy concluded
that based upon their marker results, angiosarcoma of
the face and scalp can be interpreted as consistent with
being of lymphatic derivation, but in contradistinction,
their ultrastructural studies showed features suggestive
of blood vascular differentiation. Finally, although
Prox-1 has been examined in benign vascular neo-
plasms, we are not aware of any study beside our own
in angiosarcoma.
In our series we found VEGFR-3, D2-40 and Prox-1
immunoreactivity in 57, 53 and 76% of our tumours,
respectively, confirming that lymphatic differentiation
is common in angiosarcoma. We also observed that
immunopositivity correlated with certain morphologi-
cal features that are often attributed to lymphatic
differentiation. Specifically, there was a trend for
tumours with hobnail cytology and kaposiform archi-
tecture to be positive with these markers, including a
statistically significant association between D2-40
reactivity and hobnailing.
Armed with these results, we identified 10 angiosar-
comas that had evidence of lymphatic differentiation,
both histological and immunohistochemical, which may
be deserving of the appellation lymphangiosarcoma. All
were cutaneous tumours, nine occurring on the scalp or
face of elderly adults and one in association with chronic
lymphoedema on the lower extremity. Microscopically,
all 10 tumors had well-differentiated areas comprising
interanastomosing channels that were largely devoid of
red blood cells and lined by endothelial cells with
prominent hobnailing, had lymphoid aggregates, and
expressed multiple lymphatic antigens. Furthermore,
these tumours were significantly more likely to express
D2-40 and Prox-1. However, our case numbers are
probably too low to draw definitive conclusions from this
statistic alone.
Interestingly, we are not the first to suggest that
lymphangiosarcoma may arise outside of the setting of
lymphoedema or that it has a predilection for the scalp
and face. For example, Reed et al. in 196620 reported six
cases of lymphangiosarcoma of the scalp. These cases
were morphologically similar to our cases, with well-
differentiated areas showing hobnailing and lymphoid
aggregates. Some of their cases also had poorly differen-
tiated epithelioid and spindle cell areas, as we observed in
8 of our 10 tumours. Sordillo et al. in 198121 reported
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the clinicopathological findings in 44 lymphangiosar-
comas. This series consisted of 40 tumours associated
with chronic lymphoedema and four scalp tumours not
associated with lymphoedema. They described cuboidal
and spindled endothelial cells lining capillary spaces
without red blood cells, as well as areas resembling
Kaposi’s sarcoma and higher grade solid areas. More
recently, Hancox et al. in 2006 reported a case of
lymphangiosarcoma of the cheek that had hobnailing, a
lymphoplasmacytic infiltrate and D2-40 staining.
They concluded this tumour should be classified as
an angiosarcoma of mixed histology with lymphatic
differentiation predominating.
The 10 cases of ‘lymphangiosarcoma’ in our series had
similar poor outcomes compared with the rest of the
group. Thus, it not clear whether separating them from
other angiosarcomas is clinically important, but with
only 10 cases we would not have detected subtle
differences in behaviour. In addition, although there are
currently no specific therapies directed to tumours with
lymphatic differentiation, it is conceivable that specific
targeted therapies might be developed in the future.
In summary, based upon immunohistochemical
results, angiosarcomas often show evidence of lymphatic
differentiation. This may be explained by recapitulation
of the phenotypic plasticity evidenced by embryonic
endothelial development. Furthermore, there appears to
be a subset of angiosarcomas, which, based upon
morphology and immunohistochemistry, show more
prominent lymphatic differentiation than others. Such
tumours have a predilection for the skin of the scalp and
face, and are usually not associated with chronic
lymphoedema. Thus, the concept of lymphangiosarco-
ma, which was originally based upon clinical findings,
may be evolving towards a pathological definition.
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